Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 7/20 | 0.41 |
| ▸ | STK17B | O94768 | 4/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | BCL6 | P41182 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937307 | 0.85 | ESR1 (0.49) | STK17ASTK17BALDH1A1L3MBTL1ESR1 | |
| SCHEMBL20652230 | 0.82 | STK17A (0.42) | STK17ASTK17BALDH1A1L3MBTL1ESR1 | |
| SCHEMBL1935303 | 0.79 | STK17B (0.47) | STK17ASTK17BALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1935123 | 0.78 | ALDH1A1 (0.41) | STK17ASTK17BALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1937476 | 0.77 | GLP1R (0.44) | STK17ASTK17BALDH1A1L3MBTL1MEN1 | |
| SCHEMBL28814671 | 0.77 | STK17B (0.42) | STK17ASTK17BBCL6 | |
| SCHEMBL27987018 | 0.77 | STK17B (0.42) | STK17ASTK17BBCL6 | |
| SCHEMBL1934538 | 0.76 | STK17A (0.51) | STK17ASTK17BALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1936022 | 0.75 | STK17A (0.48) | STK17ASTK17BUTS2RALDH1A1L3MBTL1 | |
| SCHEMBL2061199 | 0.75 | STK17B (0.40) | STK17ASTK17BALDH1A1L3MBTL1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | STK17A 2888/4885STK17B 3187/4885CACNA2D1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.